Skip to main content
    F

    Fulcrum Therapeutics Inc (FULC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.71
    -0.06 (-1.59%)

    Market Cap: $287.96M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Fulcrum Therapeutics Inc (FULC) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Fulcrum Therapeutics are X4 Pharmaceuticals (XFOR), Prelude Therapeutics (PRLD) and Fennec Pharmaceuticals (FENC). By market cap, Fulcrum Therapeutics ranks 8th of the 13 companies on this page; Phathom Pharmaceuticals (PHAT) is the largest at $492.63M.

    Peer Comparison

    FULC's revenue growth of -100.0% is below the peer median of 4.6%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Fulcrum Therapeutics (FULC)$287.96MN/AN/A0.0%N/A-100.0%0.00%
    X4 Pharmaceuticals Inc (XFOR)$318.59MN/A21.7x0.0%-36.9%63.1%0.00%
    Prelude Therapeutics Inc (PRLD)$275.32MN/A16.3x-269.7%N/A41.0%0.00%
    Fennec Pharmaceuticals Inc (FENC)$410.25M159.5x6.8x3.0%N/A57.3%0.00%
    Phathom Pharmaceuticals Inc (PHAT)$492.63MN/A1.8x-30.2%11.4%71.1%0.00%
    Rocket Pharmaceuticals Inc (RCKT)$256.82MN/AN/A0.0%-2.3%0.0%0.00%
    Bicycle Therapeutics Ltd (BCYC)$236.22MN/A2.7x-169.8%N/A190.2%0.00%
    Fate Therapeutics Inc (FATE)$155.74MN/A29.7x0.0%-51.3%9.2%0.00%
    Galectin Therapeutics Inc (GALT)$307.59MN/AN/A0.0%671.1%0.0%0.00%
    Lineage Cell Therapeutics Inc (LCTX)$231.35MN/A18.7x16.2%-6.7%-61.0%0.00%
    Rezolute Inc (RZLT)$353.54MN/AN/A0.0%N/A0.0%0.00%
    Prothena Corporation plc (PRTA)$419.01MN/A7.8x-45.4%N/A-74.3%0.00%
    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)$387.16MN/AN/A0.0%N/A0.0%0.00%
    Peer median$313.09M159.5x12.0x0.0%-4.5%4.6%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Fulcrum Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    X4 Pharmaceuticals Inc (XFOR)
    X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development...
    XFOR competitors
    Prelude Therapeutics Inc (PRLD)
    Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized...
    PRLD competitors
    Fennec Pharmaceuticals Inc (FENC)
    Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States.
    FENC competitors
    Phathom Pharmaceuticals Inc (PHAT)
    Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
    PHAT competitors
    Rocket Pharmaceuticals Inc (RCKT)
    Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases.
    RCKT competitors
    Bicycle Therapeutics Ltd (BCYC)
    Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments.
    BCYC competitors
    Fate Therapeutics Inc (FATE)
    Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally.
    FATE competitors
    Galectin Therapeutics Inc (GALT)
    Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic...
    GALT competitors
    Lineage Cell Therapeutics Inc (LCTX)
    Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment...
    LCTX competitors
    Rezolute Inc (RZLT)
    Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States.
    RZLT competitors
    Prothena Corporation plc (PRTA)
    Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases...
    PRTA competitors
    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
    Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies...
    CTNM competitors

    Frequently Asked Questions About FULC

    Who are Fulcrum Therapeutics' main competitors?

    The companies most similar to Fulcrum Therapeutics include X4 Pharmaceuticals (XFOR), Prelude Therapeutics (PRLD), Fennec Pharmaceuticals (FENC), Phathom Pharmaceuticals (PHAT) and Rocket Pharmaceuticals (RCKT), listed from the closest match.

    Who is Fulcrum Therapeutics' biggest competitor?

    Phathom Pharmaceuticals (PHAT) is the largest of the similar companies at $492.63M; X4 Pharmaceuticals (XFOR) is the closest match by business profile, size, sector and industry.

    How does FULC stock compare with its competitors?

    FULC's net margin is 0.0% against a peer median of 0.0%.

    Which of Fulcrum Therapeutics' competitors pays a higher dividend?

    Fulcrum Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Fulcrum Therapeutics bigger than its competitors?

    No. Fulcrum Therapeutics is 8th by market cap among the 13 companies on this page; the largest is Phathom Pharmaceuticals (PHAT) at $492.63M.